MINNEAPOLIS, MN—Fewer than one-quarter of patients who have heart failure with reduced ejection (HFrEF) and no clinical ...

Evidence supporting inflammation’s ties to cardiovascular disease is “no longer exploratory but is compelling and clinically ...

The data aren’t definitive, but continuing OAC or switching to another drug doesn’t seem to be enough for this high-risk ...

As a complement to other biomarkers, the cytokine may aid in the decision to send patients home from the ED or admit them.

The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.

Patients had less clinical worsening when treated with this “wonder drug,” as one doctor called it, within a year of ...

Keeping these factors in check and adhering to the AHA’s Life’s Essential 8, is the best way to prevent CVD, say researchers.

It can be a sensitive topic for patients that should be broached gently, without confrontation or judgment, the committee ...

The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms ...

Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, ...

In postmenopausal women with type 2 diabetes, oral hormone replacement therapy (HRT) may increase the risk of CV events.

The exploratory, post hoc look at the trial shows curves starting to separate by month 1, supporting earlier treatment.